Activity and mode of action of acridine compounds against Leishmania donovani

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 684-690

  Mesa Valle, C M ^a   Castilla Calvente, J ^b   Sanchez Moreno, M ^b   Moraleda Lindez, V ^a   Barbe, J ^c   Osuna, A ^b  

^a UNIVERSITY OF ALMERÍA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANTIPROTOZOAL AGENT; BG 325; BG 374; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; LEISHMANIA DONOVANI; NONHUMAN; PRIORITY JOURNAL;

EID: 0029919547     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.684     Document Type: Article

References (38)

1. Baumam, R. J., P. P. Mccann, and A. P. Bitonti. 1991. Suppression of Leishmama donovani by oral administration of a bis-(benzyl)polyamine analog Antimicrob. Agents Chemother. 35:1403-1407.
2. Bergmeyer, H. R. 1988 Methods of enzymatic analysis (Bergmeyer, H. R., Bergmeyer, J. and Grabl, M.) VCM, Weinheim.
3. Berman, J. D. 1981. Activity of imidazoles against Leishmania tropica in human macrophage cultures Am. J. Trop. Med. Hyg. 31:566-569.
4. Berman, J. D., J. D. Chulay, L. D. Hendricks, and C. N. Oster. 1982. Susceptibility of clinical sensitive and resistant Leishmania to pentavalent antimony in vitro J. Infect Dis. 31:459-465.
5. Berny, H., N. Bsiri, J. J. Charbit, A. M. Galy, J. C. Soyfer, J. P. Galy, J. Barbe, D. Sharples, C. M. Mesa-Valle, C. Masearó, and A. Osuna. 1992. 1,4-Dimethoxy-9(10H)-acridinone derivatives. synthesis, DNA binding studies and trypanocidal activity Arzneim Forsch. 42:674-679.
6. Braconier, J. H., and H. Miorner. 1993. Recurrent episodes of thrombocytopenia during treatment with sodium stibogluconate J. Antimicrob Chemother. 31:187-188.
7. Bryceson, A. 1987. In W. Peters and R. Killick-Kendrick (ed.), The leishmaniasis, vol. II. Academic Press, London.
8. Bryceson, A. D. M. 1970. Diffuse cutaneous leishmaniasis. II Treatment Trans R Soc. Trop. Med. Hyg. 64:369-370.
9. 1H]NMR characterization of amastigote-like forms Mol Cell. Biochem. 142:89-97.
10. Chang, K. P. 1980. Human cutaneous leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 209:1240-1242.
11. Covey, J. M., K. W. Kohn, D. Kerrigan, E. J. Tilchen, and Y. Pommier. 1988 Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res. 48:860-865.
12. Croft, S. L., R. N. Davidson, and E. A. Thornton. 1991. Liposomal amphotericin-B in the treatment of visceral leishmaniasis. J. Antimicrob Chemother. 28:111-118
13. Croft, S. L., and J. Hogg. 1988. Limited activity of bacterial DNA topoisomerase II inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Trans. R. Soc Trop. Med. Hyg. 82:856.
14. Englund, P. T. 1983. Kinetoplast DNA. In M. Levandowsky and S. H. Hutner (ed.), Biochemistry and physiology of protozoa, 2nd ed , vol. IV Academic Press, New York.
15. Fouce, R. B., M. I. Escribano, and J. M. Alunda. 1991. Putrescine uptake regulation in response to alpha-difluoromethylornithine treatment in Leishmania infantum promastigotes. Mol. Cell. Biochem 107:127-133
16. Fujioka, H., Y. Nishiyama, H. Furukawa, and N. Kumada. 1989. In vitro and in vivo activities of atalaphillinine and related acridone alkaloids against rodent malaria. Antimicrob. Agents Chemother. 33:6-9.
17. Gonzalez, A. M., S. Castanys, A. Osuna, M. M. Herrador, and J. Dominguez. 1989. Inhibitory effect of new pyrimidine bases on Trypanosoma cruzi. Arch. Pharm. (Weinheim) 322:843-846.
18. Gonzalez-Perdomo, M., S. L. De Castro, M. N. Meirelles, and S. Goldenberg. 1990 Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob. Agents Chemother. 34:1707-1714.
19. Hannun, Y., and R. M. Bell. 1988. Aminoacridines, potent inhibitors of protein kinasa C J. Biol. Chem. 263:5124-5131
20. Lun-ZR, and S. S. Desser. 1995 Is the broad range of hosts and geographical-distribution of Trypanosome evansi attributable to the loss of maxicircle kinetoplast DNA?. Parasitol Today 11:131-133.
21. Manson-Bahr, P. E. C., and F. I. C. Apted. 1982. Leishmaniasis, p. 93-115. In B. Tindall (ed.), Manson's tropical diseases. London.
22. Marr, J. J. 1991. Purine analogs as chemotherapeutic agents in leishmaniasis and American tripanosomiasis. J. Lab. Clin. Med. 118:111-119.
23. Mauel, J., W. Denny, S. Gamage, A. Ransijn, S. Wojeik, D. Figgitt, and R. Ralph. 1993. 9-Anilinoacridines as potential antileishmanial agents. Antimicrob. Agents Chemother. 37:5-9
24. Melendy, T., C. Sheline, and D. S. Ray. 1988. Localization of a type II DNA topoisomerase to two sites at the periphery of the kinetoplast DNA of Crithidia fasciculata. Cell 55:1083-1088.
25. Mesa-Valle, C. M., D. Craciunescu, E. Parrondo-Iglesias, and A. Osuna. 1991. In vitro action of platinum (II) and platinum (IV) complexes on Trypanosoma cruzi and Leishmania donovani. Arzneim. Forsch 39:838-842.
26. Moorman, A. R., S. W. Lafon, D. J. Nelson, H. H. Carter, J. J. Marr, and R. L. Berens. 1991. Antiprotozoal activity of 3′-deoxyinosine - inverse cor relation to cleavage of the glycosidic bond. Biochem. Pharmacol. 42:207-212.
27. Nelson, E. M., K. M. Tewey, and L. F. Liu. 1984 Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad Sci USA 81:1361-1365.
28. Osuna, A., S. Castanys, G. Ortega, F. Gamarro, J. Aneiros, M. F. Braña, and C. M. Roldan. 1983. Estudio ultraestructural de la acción de 2 derivados benzo(de)isoquinolil-1,3-diona sobre Trypanosoma cruzi. Rev. Inst. Med Trop. Sao Paulo 25:133-138.
29. Pearson, R. D., and A. Q. Sousa. 1985. Leishmania species: kala-azar, cutaneous and mucocutaneous leishmaniasis. p. 1522-1531. In G. L. Mandell. R G. Douglas, Jr., and J. E Bennett (ed.), Principles and practice of infectious diseases. John Wiley and Sons, New York
30. Queener, S. F., H. Fujioka, Y. Nishiyama, H. Funikawa, M. S. Bartlett, and J. W. Smith. 1991. In vitro activities of acridone alkaloids against Pneumocystis carinii. Antimicrob. Agents Chemother. 35:377-379.
31. Ram, V. J., N. Haque, and P. Y. Guru. 1992. Chemotherapeutic agents. XXI Synthesis of π-deficient pyrimidines as leishmanicides. Eur. J. Med. Chem. 27:851.
32. Segovia, M., M. Canteras, and J. M. Artero. 1984. Leishmaniasis experimental. I. Estudio de la infección cutánea y viscéral en ratones BALB/C. Rev. Iber. Parasitol. 44:265-278.
33. Steck, E. A. 1974. In E. Jucker (ed.), The leishmaniasis in progress in drug research. Birkhauser Verlag, Basel.
34. Stuart, K. 1980. Cultivation of dyskinetoplastic-Trypanosoma brucei J. Parasitol. 66:1060-1061
35. Trotter, E. R., W. Peters, and B. L. Robinson. 1980 The experimental chemotherapy of leishmaniasis. IV. The development of rodent models for visceral infection. Ann. Trop. Med Parasitol. 74:127-138.
36. Veiga, J. P. R., T. T. Rosa, T. Kimachi, E. R. Wolff, R. N. Sampaio, A. R. T. Gagliardi, L. F. Junqueira, Jr., J. M. L. Costa, and P. D. Marsden. 1985 Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Revista Inst. Med. Trop. Sao Paulo 27:298-302.
37. Wang, J. C. 1985. DNA topoisomerases. Annu Rev. Biochem. 54:665-697
38. Werbobetz, K. A., E. K. Lehnert, T. L. Macdonald, and R. D. Pearson. 1992. Cytotoxixity of acridine compounds for leishmania promastigotes in vitro. Antimicrob. Agents Chemother. 36:495-497.